vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $15.8M, roughly 1.2× Spire Global, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -176.6%, a 175.8% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -26.9%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-16.2M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -32.6%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.
CTMX vs SPIR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $15.8M |
| Net Profit | $-154.0K | $-28.0M |
| Gross Margin | — | 40.2% |
| Operating Margin | -6.9% | -164.1% |
| Net Margin | -0.8% | -176.6% |
| Revenue YoY | -25.7% | -26.9% |
| Net Profit YoY | 97.6% | 42.7% |
| EPS (diluted) | — | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.8M | ||
| Q3 25 | — | $12.7M | ||
| Q2 25 | $18.7M | $19.2M | ||
| Q1 25 | $50.9M | $23.9M | ||
| Q4 24 | $38.1M | $21.7M | ||
| Q3 24 | $33.4M | $28.6M | ||
| Q2 24 | $25.1M | $25.4M | ||
| Q1 24 | $41.5M | $34.8M |
| Q4 25 | — | $-28.0M | ||
| Q3 25 | — | $-19.7M | ||
| Q2 25 | $-154.0K | $119.6M | ||
| Q1 25 | $23.5M | $-20.7M | ||
| Q4 24 | $18.9M | $-48.8M | ||
| Q3 24 | $5.7M | $-12.5M | ||
| Q2 24 | $-6.5M | $-16.6M | ||
| Q1 24 | $13.8M | $-25.5M |
| Q4 25 | — | 40.2% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 48.9% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | — | 44.5% | ||
| Q2 24 | — | 43.0% | ||
| Q1 24 | — | 26.5% |
| Q4 25 | — | -164.1% | ||
| Q3 25 | — | -166.1% | ||
| Q2 25 | -6.9% | -122.7% | ||
| Q1 25 | 44.4% | -106.5% | ||
| Q4 24 | 46.4% | -144.1% | ||
| Q3 24 | 12.3% | -48.0% | ||
| Q2 24 | -33.7% | -48.6% | ||
| Q1 24 | 28.1% | -34.4% |
| Q4 25 | — | -176.6% | ||
| Q3 25 | — | -155.3% | ||
| Q2 25 | -0.8% | 623.4% | ||
| Q1 25 | 46.2% | -86.5% | ||
| Q4 24 | 49.6% | -225.2% | ||
| Q3 24 | 17.2% | -43.7% | ||
| Q2 24 | -26.0% | -65.2% | ||
| Q1 24 | 33.3% | -73.3% |
| Q4 25 | — | $-0.85 | ||
| Q3 25 | — | $-0.61 | ||
| Q2 25 | — | $3.72 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-1.93 | ||
| Q3 24 | — | $-0.50 | ||
| Q2 24 | — | $-0.68 | ||
| Q1 24 | — | $-1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $112.9M |
| Total Assets | $175.1M | $211.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $81.8M | ||
| Q3 25 | — | $96.8M | ||
| Q2 25 | $49.0M | $117.6M | ||
| Q1 25 | $47.6M | $35.9M | ||
| Q4 24 | $38.1M | $19.2M | ||
| Q3 24 | $40.6M | $36.6M | ||
| Q2 24 | $43.2M | $45.8M | ||
| Q1 24 | $36.2M | $63.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $103.7M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $123.1M |
| Q4 25 | — | $112.9M | ||
| Q3 25 | — | $133.1M | ||
| Q2 25 | $119.9M | $149.2M | ||
| Q1 25 | $25.0M | $3.7M | ||
| Q4 24 | $-456.0K | $-11.7M | ||
| Q3 24 | $-23.5M | $30.8M | ||
| Q2 24 | $-31.2M | $40.3M | ||
| Q1 24 | $-31.7M | $52.5M |
| Q4 25 | — | $211.0M | ||
| Q3 25 | — | $224.3M | ||
| Q2 25 | $175.1M | $239.5M | ||
| Q1 25 | $98.5M | $208.8M | ||
| Q4 24 | $120.5M | $193.6M | ||
| Q3 24 | $139.0M | $224.2M | ||
| Q2 24 | $159.2M | $230.8M | ||
| Q1 24 | $184.7M | $252.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 27.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 2.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-4.3M |
| Free Cash FlowOCF − Capex | $-15.8M | $-16.2M |
| FCF MarginFCF / Revenue | -84.6% | -102.1% |
| Capex IntensityCapex / Revenue | 0.1% | 75.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-92.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | $-15.8M | $-35.1M | ||
| Q1 25 | $-21.0M | $-8.4M | ||
| Q4 24 | $-19.9M | $-19.2M | ||
| Q3 24 | $-20.7M | $14.0M | ||
| Q2 24 | $-19.5M | $-4.4M | ||
| Q1 24 | $-26.0M | $-8.8M |
| Q4 25 | — | $-16.2M | ||
| Q3 25 | — | $-20.4M | ||
| Q2 25 | $-15.8M | $-38.7M | ||
| Q1 25 | $-21.2M | $-17.3M | ||
| Q4 24 | $-20.0M | $-24.3M | ||
| Q3 24 | $-20.7M | $5.1M | ||
| Q2 24 | $-19.6M | $-9.9M | ||
| Q1 24 | $-26.2M | $-15.9M |
| Q4 25 | — | -102.1% | ||
| Q3 25 | — | -161.3% | ||
| Q2 25 | -84.6% | -201.7% | ||
| Q1 25 | -41.6% | -72.6% | ||
| Q4 24 | -52.5% | -112.2% | ||
| Q3 24 | -62.1% | 17.8% | ||
| Q2 24 | -78.2% | -39.0% | ||
| Q1 24 | -63.1% | -45.7% |
| Q4 25 | — | 75.1% | ||
| Q3 25 | — | 66.2% | ||
| Q2 25 | 0.1% | 18.8% | ||
| Q1 25 | 0.2% | 37.3% | ||
| Q4 24 | 0.2% | 23.5% | ||
| Q3 24 | 0.1% | 31.2% | ||
| Q2 24 | 0.4% | 21.8% | ||
| Q1 24 | 0.3% | 20.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.29× | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SPIR
Segment breakdown not available.
